MedTrace Logo

Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis

NCT04315480 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2020-04-13

No results posted yet for this study

Summary

In a Phase 2 Simon's Optimal Two-Stages Design intravenous tocilizumab will be administered as single 8mg/Kg dose in patients affected by severe multifocal interstitial pneumonia correlated to SARS-CoV2 infection. Aim of the study is to test the hypothesis that an anti-IL6 treatment can be effective in calming the virus-induced cytokine storm, blocking deterioration of lung function or even promoting a rapid improvement of clinical conditions, preventing naso-tracheal intubation and/or death.

Conditions

  • SARS Pneumonia

Interventions

DRUG

Tocilizumab

single intravenous administration 8mg/Kg

Sponsors & Collaborators

  • Azienda Ospedaliera Ospedali Riuniti Marche Nord

    collaborator UNKNOWN

  • Università Politecnica delle Marche

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-12
Primary Completion
2020-04-09
Completion
2020-05-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04315480 on ClinicalTrials.gov